Dogwood Therapeutics (NASDAQ:DWTX – Get Free Report) is expected to issue its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of ($0.15) per share for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 12:30 PM ET.
Dogwood Therapeutics (NASDAQ:DWTX – Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.20). On average, analysts expect Dogwood Therapeutics to post ($0.80) EPS for the current fiscal year and ($0.66) EPS for the next fiscal year.
Dogwood Therapeutics Stock Performance
Shares of Dogwood Therapeutics stock opened at $1.22 on Tuesday. Dogwood Therapeutics has a twelve month low of $1.07 and a twelve month high of $7.04. The company’s 50 day moving average is $1.66 and its 200 day moving average is $1.98.
Wall Street Analysts Forecast Growth
Several equities analysts have recently weighed in on the company. HC Wainwright reissued a “buy” rating on shares of Dogwood Therapeutics in a report on Wednesday, September 2nd. Weiss Ratings reissued a “sell (e+)” rating on shares of Dogwood Therapeutics in a report on Thursday, October 22nd. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $12.00.
Read Our Latest Analysis on Dogwood Therapeutics
About Dogwood Therapeutics
Dogwood Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing antiviral therapies for diseases associated with viral activation. The company’s programs are designed to address conditions for which persistent or reactivated viral activity may contribute to symptoms and disease progression.
Its lead investigational product, IMC-1, is an oral combination of the antiviral drug famciclovir and the anti-inflammatory drug celecoxib. The company has evaluated IMC-1 in fibromyalgia and has also investigated its potential use in other conditions, including symptoms associated with long COVID.
Read More
- Five stocks we like better than Dogwood Therapeutics
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AI—These 5 Stocks Are Getting Paid
Receive News & Ratings for Dogwood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dogwood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
